Vaxcyte COO Jim Wassil exercises 2,250 options

The reported stock-option position was 44,148 shares after exercise, while the same-day sales followed a plan adopted December 9, 2025.

Available on EDGAR 11/04/2026 - 04:52 PM EST Accepted by SEC EDGAR 11/04/2026 - 04:51 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) EVP, Chief Scientific Officer and COO Jim Wassil exercised options for 2,250 common shares on November 2, 2026, at a $5.35 exercise price. He sold 1,907 shares at a weighted-average $60.779 and 343 shares at a weighted-average $61.57 that day; both sales were made under a Rule 10b5-1 trading plan adopted December 9, 2025. The reported stock-option position following the exercise was 44,148 shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 2,250 shares ($125K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Wassil Jim

Role EVP, Chief Scientific Ofc, COO

Sold 2,250 shs ($137K)

Approx. gross sale proceeds $137K

Approx. exercise cost $12K

Approx. pre-tax spread $125K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F4	2,250	$0.00	$0.00
Exercise	Common Stock	2,250	$5.35	$12K
Sale	Common Stock F1, F2	1,907	$60.779	$116K
Sale	Common Stock F1, F3	343	$61.57	$21K

Holdings After Transaction: Stock Option (right to buy) — 44,148 contracts (Direct); Common Stock — 145,435 shares (Direct)

Footnotes (4)

1. F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
2. F2. The price reported is a weighted-average price. The shares were sold at prices ranging from $60.385 to $61.24. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price
3. F3. The price reported is a weighted-average price. The shares were sold at prices ranging from $61.40 to $61.88. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price
4. F4. Stock Option is fully vested and exercisable.

Key Figures

Shares acquired through option exercise: 2,250 common shares Exercise price: $5.35 per share Shares sold: 1,907 shares +2 more

5 metrics

Shares acquired through option exercise 2,250 common shares November 2, 2026

Exercise price $5.35 per share Option exercise on November 2, 2026

Shares sold 1,907 shares Weighted-average sale price of $60.779 on November 2, 2026

Shares sold 343 shares Weighted-average sale price of $61.57 on November 2, 2026

Shares underlying stock options following transaction 44,148 shares Reported following the November 2, 2026 option transaction

Key Terms

Rule 10b5-1 trading plan, weighted-average price, fully vested and exercisable

3 terms

Rule 10b5-1 trading plan regulatory

"effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

fully vested and exercisable financial

"Stock Option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Jim Wassil sell and at what prices in PCVX?

Jim Wassil sold 1,907 shares at a weighted-average price of $60.779 and 343 shares at a weighted-average price of $61.57 on November 2, 2026. The sales were made under a Rule 10b5-1 trading plan adopted December 9, 2025. The respective sale-price ranges were $60.385 to $61.24 and $61.40 to $61.88.

How many PCVX options did Jim Wassil exercise and at what price?

Jim Wassil exercised options for 2,250 common shares at a $5.35 exercise price on November 2, 2026. The option was fully vested and exercisable, and the reported stock-option position following the transaction was 44,148 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wassil Jim

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Scientific Ofc, COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/02/2026		M		2,250	A	$5.35	147,685	D
Common Stock	11/02/2026		S(1)		1,907	D	$60.779(2)	145,778	D
Common Stock	11/02/2026		S(1)		343	D	$61.57(3)	145,435	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.35	11/02/2026		M			2,250	(4)	04/17/2030	Common Stock	2,250	$0	44,148	D

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.

2. The price reported is a weighted-average price. The shares were sold at prices ranging from $60.385 to $61.24. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price

3. The price reported is a weighted-average price. The shares were sold at prices ranging from $61.40 to $61.88. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price

4. Stock Option is fully vested and exercisable.

Remarks:

	Jim Wassil, by /s/ Peter N. Efremenko, Attorney-In-Fact	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)